Spruce Biosciences Inc. (SPRB) News
Filter SPRB News Items
SPRB News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest SPRB News From Around the Web
Below are the latest news stories about SPRUCE BIOSCIENCES INC that investors may wish to consider to help them evaluate SPRB as an investment opportunity.
Spruce Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate UpdatesSOUTH SAN FRANCISCO, Calif., November 13, 2023--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the third quarter ended September 30, 2023 and provided corporate updates. |
Spruce Biosciences to Participate in the Jefferies London Healthcare ConferenceSOUTH SAN FRANCISCO, Calif., November 02, 2023--Spruce Biosciences to Participate in the Jefferies London Healthcare Conference |
Spruce Biosciences Completes Target Enrollment of CAHmelia-203 Study in Adult Classic Congenital Adrenal HyperplasiaSOUTH SAN FRANCISCO, Calif., October 18, 2023--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced completion of target enrollment of 72 patients and closure of screening in the CAHmelia-203 clinical trial evaluating tildacerfont for the treatment of adult classic congenital adrenal hyperplasia (CAH) and provided updated anticipat |
Spruce Biosciences to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceSOUTH SAN FRANCISCO, Calif., August 28, 2023--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference on September 12, 2023, at 3:30 p.m. ET. |
Spruce Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate UpdatesSOUTH SAN FRANCISCO, Calif., August 14, 2023--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the second quarter ended June 30, 2023 and provided corporate updates. |
Spruce Biosciences, Inc. (SPRB) Upgraded to Buy: Here's WhySpruce Biosciences, Inc. (SPRB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
Spruce Biosciences Announces Acceptance of Abstract for Presentation at the Annual Meeting of the Endocrine Society (ENDO 2023)SOUTH SAN FRANCISCO, Calif., June 12, 2023--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that a submitted abstract was accepted for the 105th Annual Meeting of the Endocrine Society (ENDO 2023) taking place June 15-18, 2023, in Chicago. In a poster presentation, the company will highlight the effect of tildacerfont on gonad |
Spruce Biosciences Appoints Percival Barretto-Ko to Board of DirectorsSOUTH SAN FRANCISCO, Calif., May 25, 2023--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced the appointment of Percival Barretto-Ko to the company’s Board of Directors. Concurrently, Dina Chaya, Ph.D., has stepped down from the Board of Directors. |
Spruce Biosciences to Participate in the Jefferies Healthcare ConferenceSOUTH SAN FRANCISCO, Calif., May 24, 2023--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the Jefferies Healthcare Conference on June 9, 2023, at 9:30 a.m. ET. |
Spruce Biosciences Honored at CARES Foundation 15th Annual Everyone CARES GalaSOUTH SAN FRANCISCO, Calif., May 22, 2023--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, was honored by the CARES Foundation, Inc. for its ongoing development of tildacerfont for patients with classic congenital adrenal hyperplasia (CAH). The CARES Foundation is the only U.S.-based nonprofit organization solely dedicated to improving the li |